Focused ultrasound trial for rare sarcoma halted early
NCT ID NCT04123535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether focused ultrasound could partially destroy a rare soft-tissue cancer called undifferentiated pleomorphic sarcoma and boost the body's immune response. Only 5 people were enrolled before the trial was terminated. The main goal was to check safety and see if the treatment changed immune cell levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Magnetic Resonance-guided Focused Ultrasound (MRgFUS) device
- What this could lead to
- If successful, this approach could help the immune system fight sarcoma more effectively, potentially improving treatment options.
- What could go wrong
- The trial was terminated early and enrolled only 5 people, so results are very limited. The approach is still experimental and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Blood test may spot hidden sarcoma signals
- Immunotherapy boosts chemo against rare sarcomas?
- New combo therapy aims to shrink sarcomas
- New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
- Experimental drug tested for rare cancer, trial stopped early